Capsida Biotherapeutics

Cell & Gene Therapy · Biotechnology
Clinical trials: 3No open roles listed
Data updated Nov 21, 2026Full reportReport a mistake
Lately:1 news story in 90 daysFollow changes →

Facts

as of Nov 21, 2026

Capsida Biotherapeutics is an industry-leading gene therapy platform company creating a new class of targeted, non-invasive gene therapies for patients with debilitating and life-threatening disorders.

Founded
2019
Official records
Wikidata Q119857248
Sources: company registers, GLEIF, Wikidata, the company's site, Alion job postingsReport a mistake

Products

Products →

Capsida Biotherapeutics has 3 clinical trials on record, 0 under way.

Clinical trials
A Clinical Trial of CAP-003 Gene Therapy in Adult Patients With GBA1 Associated Parkinson's Disease
phase 2 · stopped or withdrawn · GBA1 Parkinson Disease
Aug 2025
A Clinical Trial of CAP-002 Gene Therapy in Pediatric Patients With Syntaxin-Binding Protein 1 (STXBP1) Encephalopathy
phase 2 · stopped or withdrawn · 1 participants · Developmental and Epileptic Encephalopathy
Jul 2025
Natural History Study in Pediatric Patients with STXBP1 Encephalopathy with Epilepsy
stopped or withdrawn · STXBP1 Encephalopathy with Epilepsy
Oct 2024
Source: each app’s App Store and Google Play page (an app counts as the company’s when its developer site is on the company’s domain); the products its own site names.

Capsida Biotherapeutics: 9 research papers in five years.

Sanctions lists
OFAC SDN, EU consolidated
No match
Phishing reports
OpenPhish, Phishing.Database
None
Layoff notices
US WARN notices on file
None
Full employer checkScam signs in adverts, mail records, visa registers, domain history
Sources: company registers, the Alion truth index, OFAC and EU sanctions lists, US WARN notices
Milestones
Founded
2019
Sources: the outlets named on each headline, each story once